Paragon Financial Partners Inc. Lowers Position in Johnson & Johnson (NYSE:JNJ)

Paragon Financial Partners Inc. reduced its stake in Johnson & Johnson (NYSE:JNJGet Rating) by 4.7% in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 4,379 shares of the company’s stock after selling 217 shares during the quarter. Johnson & Johnson makes up 0.8% of Paragon Financial Partners Inc.’s investment portfolio, making the stock its 22nd largest holding. Paragon Financial Partners Inc.’s holdings in Johnson & Johnson were worth $715,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also bought and sold shares of JNJ. Morton Brown Family Wealth LLC grew its stake in Johnson & Johnson by 78.0% in the 2nd quarter. Morton Brown Family Wealth LLC now owns 178 shares of the company’s stock valued at $32,000 after purchasing an additional 78 shares during the period. Goodman Advisory Group LLC bought a new position in Johnson & Johnson in the 2nd quarter valued at $39,000. Cardinal Capital Management Inc. grew its stake in Johnson & Johnson by 333.3% in the 2nd quarter. Cardinal Capital Management Inc. now owns 260 shares of the company’s stock valued at $46,000 after purchasing an additional 200 shares during the period. First Bank & Trust grew its stake in Johnson & Johnson by 69.6% in the 2nd quarter. First Bank & Trust now owns 380 shares of the company’s stock valued at $67,000 after purchasing an additional 156 shares during the period. Finally, Heritage Wealth Management LLC bought a new position in Johnson & Johnson in the 2nd quarter valued at $84,000. 67.94% of the stock is owned by hedge funds and other institutional investors.

Johnson & Johnson Stock Performance

NYSE:JNJ opened at $173.43 on Friday. The business’s 50-day moving average price is $176.32 and its two-hundred day moving average price is $171.55. Johnson & Johnson has a twelve month low of $155.72 and a twelve month high of $186.69. The stock has a market cap of $453.43 billion, a P/E ratio of 24.15, a PEG ratio of 3.45 and a beta of 0.56. The company has a quick ratio of 1.18, a current ratio of 1.43 and a debt-to-equity ratio of 0.37.

Johnson & Johnson (NYSE:JNJGet Rating) last released its quarterly earnings results on Tuesday, October 18th. The company reported $2.55 earnings per share for the quarter, beating the consensus estimate of $2.49 by $0.06. Johnson & Johnson had a return on equity of 35.37% and a net margin of 19.95%. The firm had revenue of $23.79 billion for the quarter, compared to analysts’ expectations of $23.44 billion. During the same quarter last year, the firm posted $2.60 EPS. The company’s revenue was up 1.9% compared to the same quarter last year. As a group, equities analysts predict that Johnson & Johnson will post 10.04 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, March 7th. Shareholders of record on Tuesday, February 21st will be issued a $1.13 dividend. The ex-dividend date is Friday, February 17th. This represents a $4.52 annualized dividend and a dividend yield of 2.61%. Johnson & Johnson’s payout ratio is currently 62.95%.

Insider Buying and Selling at Johnson & Johnson

In related news, insider William Hait sold 15,000 shares of the firm’s stock in a transaction dated Monday, October 24th. The stock was sold at an average price of $171.55, for a total transaction of $2,573,250.00. Following the transaction, the insider now directly owns 80,236 shares of the company’s stock, valued at approximately $13,764,485.80. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. In related news, CFO Joseph J. Wolk sold 14,781 shares of the firm’s stock in a transaction dated Tuesday, December 13th. The stock was sold at an average price of $179.60, for a total transaction of $2,654,667.60. Following the transaction, the chief financial officer now directly owns 35,812 shares of the company’s stock, valued at approximately $6,431,835.20. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider William Hait sold 15,000 shares of the firm’s stock in a transaction dated Monday, October 24th. The shares were sold at an average price of $171.55, for a total value of $2,573,250.00. Following the transaction, the insider now directly owns 80,236 shares in the company, valued at $13,764,485.80. The disclosure for this sale can be found here. Insiders have sold a total of 300,750 shares of company stock valued at $52,311,677 in the last 90 days. Corporate insiders own 0.35% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on JNJ. Citigroup upped their price objective on Johnson & Johnson from $198.00 to $205.00 and gave the company a “buy” rating in a research note on Monday, December 12th. Barclays began coverage on Johnson & Johnson in a research note on Monday, October 17th. They set an “equal weight” rating and a $175.00 price target for the company. Morgan Stanley cut their price target on Johnson & Johnson from $178.00 to $176.00 and set an “equal weight” rating for the company in a research note on Tuesday, December 6th. Credit Suisse Group began coverage on Johnson & Johnson in a research note on Thursday, November 17th. They set a “neutral” rating and a $170.00 price target for the company. Finally, Sanford C. Bernstein cut their price target on Johnson & Johnson from $194.00 to $190.00 in a research note on Wednesday, October 19th. Seven equities research analysts have rated the stock with a hold rating, four have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $182.42.

About Johnson & Johnson

(Get Rating)

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.

See Also

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJGet Rating).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.